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It has been previously proposed that nitric oxide (NO) is the
only biologically relevant nitrogen oxide capable of activating
the enzyme soluble guanylate cyclase (sGC). However, recent
reports implicate HNO as another possible activator of sGC.
Herein, we examine the affect of HNO donors on the activity of
purified bovine lung sGC and find that, indeed, HNO is capable
of activating this enzyme. Like NO, HNO activation appears to
occur via interaction with the regulatory ferrous heme on sGC.
Somewhat unexpectedly, HNO does not activate the ferric form
of the enzyme. Finally, HNO-mediated cysteine thiol modifica-
tion appears to also affect enzyme activity leading to inhibition.
Thus, sGC activity can be regulated by HNO via interactions at
both the regulatory heme and cysteine thiols.
Nitric oxide (NO)2 is the most studied of the endogenously
generated nitrogen oxides and is well known to mediate many
aspects of cardiovascular function including the regulation of
vascular tone and platelet aggregation (for example, see Ref. 1).
These responses are in large part due to the interaction of NO
with its most established endogenous receptor, soluble guany-
late cyclase (sGC) (2). This 150-kDa heterodimeric heme pro-
tein catalyzes the production of the secondmessengermolecule
cyclic guanosine monophosphate (cGMP) from guanosine
triphosphate (GTP) (3). The basal activity of sGC is enhanced
several hundred fold upon binding of NO to the single regula-
tory heme site. This stimulation of activity is a result of a con-
formational change induced by cleavage of the proximal histi-
dine heme ligand upon formation of the ferrous nitrosyl
complex, which is preferentially pentacoordinate (4). In addi-
tion to heme site regulation of sGC, there are numerous reports
indicating that oxidation of cysteine thiol residues on this pro-
tein can also alter/regulate both the basal activity and the
degree of NO-mediated activation (5–10).
Recently, the one-electron reduced andprotonated congener
of NO, nitroxyl (HNO) has received significant interest as a
cardiovascular agent whose actions are independent of NO for-
mation (11). For example, a study by Ellis and co-workers (12)
suggests that HNO is a vital component of endothelium-de-
rived relaxing factor along with NO in rat aorta. HNO is also
able to mediate murine aorta vasorelaxation even in the pres-
ence of NO scavengers (13). Furthermore, the vasodilation pro-
duced by HNO was inhibited by the sGC heme site inhibitor,
1H-[1,2,4]oxadiazolo[4,3-a]-quinoxalin-1-one implicating sGC
activation in this HNO-mediated effect. In addition to its
effects on large conduit vessels like the aorta, HNO also dilates
rat small mesenteric resistance-like arteries through sGC-de-
pendent and voltage-dependent K channel-dependent mech-
anisms (14). Nitroxyl (derived from the HNO-donor Angeli’s
salt) is also a potent dilator of feline pulmonary vasculature
equal to that of the NO donors SPER/NO, DETA/NO, and
SULFI/NO (15). Most recently, HNO was found to be a potent
dilator of rat coronary arteries through an sGC-mediated
mechanism (16). The evidence presented in these studies sug-
gests that HNO is able to modulate cGMP levels through an
interaction with sGC, an idea in conflict with a previous report
showing that NO is the only nitrogen oxide capable of directly
activating sGC (17).
HNO forms a stable adduct with the ferrous heme of
deoxymyoglobin (18, 19) providing precedence for a possible
interaction between HNO and sGC that is akin to the inter-
action of NO with ferrous sGC. In light of all the reports
indicating possible HNO-mediated activation of sGC, an
examination of the direct interaction of HNO with purified
sGC was carried out to evaluate the possibility that HNO
may be capable of directly interacting with sGC to elicit acti-
vation. Moreover, due to the previously reported thiol redox
regulation of sGC (see above) and the known thiophilicity of
HNO (20), we also examined the effects of HNO-mediated
thiol modification on enzyme activity.
EXPERIMENTAL PROCEDURES
Materials
Sodium trioxodinitrate (Angeli’s salt, AS) was synthesized by
the general method of Smith and Hein (21). Diethylamine
NONOate (DEA/NO)was synthesized following themethod of
Drago and Paulik (22). 1-Nitrosocyclohexyl trifluoroacetate
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(NCTFA) was synthesized according to Sha et al. (23). Trieth-
anolamine hydrochloride (TEA), DL-dithiothreitol (DTT),
L-cysteine, EDTA, guanosine triphosphate sodium salt (GTP),
protoprophyrin IX (PPIX), hemin chloride, 3-isobutyl-1-meth-
ylxanthine, hydroxylamineHCl, K3Fe(CN)6, and sodiumnitrite
were all purchased from Sigma, in the highest purity available.
MgCl26H2O was purchased from Mallinckrodt (Hazelwood,
MO). Tween 20 (enzyme grade) was purchased from Fisher
(Pittsburgh, PA). 1H-[1,2,4]Oxadiazolo[4,3-a]quinoxalin-1-
one was purchased from Cayman Chemical (Ann Arbor, MI).
NAP-10 and NAP-5 size exclusion columns and EIA kit
(RPN226) were purchased from GE Healthcare. All experi-
ments were performed anaerobically unless otherwise stated.
Methods
Purification of Soluble Guanylate Cyclase from Bovine Lung—
Bovine sGCwas isolated and purified as described previously (24).
The procedure produced sGC that was bovine serum albumin-
free byWesternblot analysis. The enzymehad a specific activity of
28.3  0.4 nmol of cGMPmin1 mg1 and was activated 27-fold
by the NO donor S-nitroso-N-acetylpenicillamine.
Soluble Guanylate Cyclase Activity Assay—The activity of
sGC was determined as previously reported (25) with slight
modifications. The enzyme reaction mixture (40 mM TEA, pH
7.4, 1 mM GTP, 3 mM MgCl2, and 0.3 mM 3-isobutyl-1-methyl-
xanthine) was premixed in bulk in a sealed round bottom flask
and deoxygenated by purging the headspace with argon for 30
minwhile stirring.All furthermanipulationswere performed in
an anaerobic chamber (Plas Labs, LansingMI). sGCwas diluted
to the appropriate concentration with cold deoxygenated
buffer (25 mM TEA, pH 7.4) and manipulated further as speci-
fied. All reactions were initiated by the addition of the enzyme
reaction mixture. The reaction was carried out for 10–20 min
at 37 °C and stopped by adding 10 l of 0.5 M EDTA to chelate
the Mg2 cofactor. Samples were stored at 20 °C until ready
to assay. Accumulated cGMP was quantified with the cGMP
EIA kit according to themanufacturer’s instructions (R&DSys-
tems, Minneapolis, MN). Samples were diluted 100–1000-fold
with EIA assay buffer for quantification.
Preparation ofNOandHNODonors andPorphyrin Solutions—
NOandHNOdonorswere taken into the anaerobic chamber as
solids or pure liquid and diluted with deoxygenated solvent
inside the chamber. All donors were made into a 200 stock to
be added in 1-l aliquots to the reaction mixture to minimize
solvent pH effects. DEA/NO andAngeli’s salt were diluted with
10mMNaOH, NCTFAwas diluted with deoxygenated dimeth-
yl sulfoxide, PPIX was diluted with deoxygenated 25 mM TEA
buffer, pH 7.4, containing 5% Tween 20. Decomposed controls
for AS and NCTFA were made by allowing the appropriate
concentration of donor to decompose overnight in 25mMTEA
buffer, pH 7.4, at 37 °C. All dilutions were performed just prior
to the beginning of the experiment.
Removal of sGC Heme—Based on a procedure by Schmidt et
al. (26), ferrous sGC was mixed with a solution containing 2%
Tween 20 and 25 mM TEA, pH 7.4, for 10 min at 37 °C. The
mixture was diluted to 0.5ml and loaded onto a NAP-5 column
previously equilibrated with deoxygenated buffer (25 mM TEA,
pH 7.4) to remove unbound heme and Tween 20.
Oxidation of Ferrous sGCwith K3Fe(CN)6—Ferrous sGCwas
mixedwith 100MK3Fe(CN)6 and incubated for 1min at 25 °C.
Thismixture was diluted to 0.5ml and passed through aNAP-5
size exclusion column previously equilibrated with deoxygen-
ated buffer (25 mM TEA, pH 7.4) to remove excess K3Fe(CN)6.
Of the 1 ml collected, half was used as the ferric form and the
other half was re-reduced with 2 mM DTT.
RESULTS
sGC Is Activated by HNO Donors—To determine whether
sGC is activated by HNO, we measured the activity of puri-
fied sGC treated with the HNO donors AS and the acyloxyni-
troso compound NCTFA. These HNO donors are structurally
dissimilar but decompose predictably in aqueous solution to
give HNO and nitrite (AS) or HNO and cyclohexanone
(NCTFA) (Fig. 1) (23, 27).
As a positive control we also examined the effect of the NO
donor DEA/NO on enzyme activity. sGC was maximally acti-
vated nearly 80-fold byDEA/NO (100M), whereas AS (10M)
activated sGC by up to 20-fold and NCTFA (100 M) activated
60-fold (Fig. 2).
To verify that sGC activation is directly dependent on HNO
release from AS and NCTFA (as opposed to other donor
byproducts), we measured sGC activity in the presence of
decomposed donors or sodium nitrite (AS decomposition co-
product). Under the same incubation conditions as before, no
activation was observed (data not shown).
Because AS and NCTFA are structurally distinct HNO
donors, enzyme activation likely occurs via HNO generation
and is not due to the donors themselves. These results thus
suggest that HNO produced from AS and NCTFA activate
sGC. We propose that HNO-mediated sGC activation can
occur in one of at least three possible ways: 1) HNO could be
converted to a very small amount ofNOwhich activates sGC; 2)
HNOcouldmodify critical thiols on sGC to affect its activity; or
3)HNOcould activate sGC via adirect interactionwith theheme
of sGC, akin to NO-mediated activation. Of course, the net
observed activation of sGC by HNO could be a combination of
some or all of these effects. The following experiments were car-
ried out to specifically address these mechanistic possibilities.
HNO (and Not NO) Is the Species Activating sGC—To test if
HNO indirectly activates sGC through conversion to NO, we
measured sGC activity in the presence of various species that
prevent HNO to NO conversion. First, HNO can be converted
to NO by adventitious oxidants present in the reagents, such as
Fe3 or Cu2 (Reaction 1) (28).
FIGURE 1. Schematic of Angeli’s salt (A) and NCTFA (B) decomposition to
yield HNO.
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HNO  Mn3 NO  Mn  1  H
REACTION 1
To eliminate contamination from metals that could lead to
the conversion of HNO to NO, the highest purity water avail-
able was used (double distilled from glass), all solutions were
passed through Chelex resin and metal chelators were used.
Traditional chelators including EDTA, EGTA, and diethylene
triamine pentacetic acid cannot be used in this case because of
their high affinity formagnesium, a required factor for the cycli-
zation reaction catalyzed by sGC. Therefore we used desferri-
oxamine for its preferential chelation of iron and copper
over magnesium (Fe3, Kb  1031; Cu2, Kb  1014, versus
Mg2, Kb  104 (29, 30)). Desferrioxamine did not effect the
ability of DEA/NO, AS, or NCTFA to activate sGC (Fig. 3A)
indicating that HNO is directly binding to sGC.
The HNO donor Angeli’s salt is known to produce trace
amounts ofNOas aminor decomposition side product (31, 32).
Because the reaction ofNOwithHNO is fast (5.8 106M1 s1
(33)), in most cases NO should be scavenged by excess HNO,
precluding any biological activity associated with NO. How-
ever, given the very high affinity of sGC for NO, it may still be
possible to observe some activity associated with NO. NCTFA,
however, does not generate NO in an alternative decomposi-
tion pathway and, therefore, represents a strict HNO donor.
Although it would be difficult to definitively validate that produc-
tionofminute levels ofNOfromAngeli’s saltwerenot responsible
for the observed activity enhancements, the problem can be refo-
cused to the effect of HNO levels on sGC activity.
It is established that HNO is efficiently scavenged by thiols
(compared with NO), an effect used previously to differenti-
ate between HNO- versus NO-mediated biological activity
(34). Thus, to determine whether the activation of sGC by
HNO donors is due to HNO release or to the small amount of
NO produced as a byproduct, DTT was co-incubated with
the donor to see if HNO scavenging by DTT can inhibit sGC
activation (Fig. 3B). DTT does not react with NO under the
conditions of our reactions (anaerobic) and, expectedly, has
very little effect on sGC activation
by DEANO. However, DTT signifi-
cantly reduces the NCTFA-medi-
ated sGC activation, suggesting that
NCTFA primarily activates sGC
through HNO generation. Interest-
ingly, DTT does not inhibit the abil-
ity of Angeli’s salt to activate sGC,
but rather potentiated the Angeli’s
salt-mediated sGC activation to the
level of DEA/NO. This result is not
necessarily surprising because DDT
will scavenge the HNO generated
from Angeli’s salt and will not react
with the trace amount of NO (see
above). Because the trace amount of
NO made by Angeli’s salt should
normally be scavenged by HNO, in
the presence of DTT, NO will “sur-
vive” to activate sGC (indeed, small
amounts of NO are observed in a decomposing solution of AS
only in the presence of DTT).3 This observation could also be
due to the differing kinetics of AS versus NCTFA decomposi-
tion (see below).
The reaction of DTT with HNO produces hydroxylamine
according to the Reaction 2 (35).
HNO  DTTred3 H2NOH  DTTox
REACTION 2
As a control, we verified that hydroxylamine did not activate
sGC (data not shown), thus ruling out a possible reaction of
DTT with HNO to generate another species (H2NOH) with
possible activity.
HNO Activates sGC by Directly Interacting with the Heme—
The established chemistry of HNO (36) predicts at least two
possible types of interaction with sGC. HNO can coordinate to
the heme site (18) and/or react with one or more of the numer-
ous cysteine thiols (20) of sGC. Because both heme coordina-
tion (byNO) and cysteine thiol redox processes are known to be
capable of regulating sGC activity (6, 37) it is clearly possible
that the observed HNO-mediated changes in sGC activity
could be due to either interaction or a combination of interac-
tions at these two targets.
Although removal of heme from sGC does not substantially
alter basal activity (26), it drastically affected activation by both
DEA/NO and HNO donors (Fig. 4A). Heme removal from sGC
decreased its sensitivity to activation by DEA/NO (from 70-fold
activation down to 20-fold) andmarkedly reduced the HNO-me-
diated activation. The small degree of activation still observed for
bothNOandHNOeven after depletion of hemewas undoubtedly
the result of the incomplete removal of heme. Complete heme
removal from sGCproved to be very difficult and complete loss of
DEA/NO-dependent activation could not be attainedwithout sig-
nificant loss of basal activity (data not shown). These results sug-
gest that sGCactivation byHNOdonors occurs via direct interac-
3 B. Mayer, personal communication.
FIGURE 2. sGC is activated by HNO donors. sGC (3.2 g final: 0.11 M) activity was measured in the presence
of NO (DEANO) or HNO (NCTFA, Angeli’s salt) donors for 16 min at 37 °C. Data represents the average of
triplicate measurements reported as fold-activation over basal activity (no donor).
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tionofHNOwith the sGCheme.The loss ofHNOactivation after
partial heme removal from sGC also implies that any significant
activationbyHNOisnotdue toany interactionbetweenHNOand
the cysteine thiols on sGC.
HNOActivates Ferrous Heme sGC—Under normal physiologi-
cal conditions, the heme in sGCexists in the ferrous state. Because
NO activates sGC via binding to the ferrous state of this enzyme
(Reaction 3), oxidation of sGC yields an NO-insensitive ferric
form, a species that may be relevant in diseased tissues (38).
sGC-Fe2  NO3 sGC-Fe2-NO activation
REACTION 3
sGCFe3  HNO3 sGCFe2NO  H activation?
REACTION 4
HNO has been shown to reductively nitrosylate other ferric
hemeproteins (39, 40) suggesting thatHNOcould interactwith
the ferric heme of sGC to give the
ferrous nitrosyl adduct, the same
product generated from the reac-
tion of NO with the ferrous form of
the enzyme (Reaction 4). Thus, it
may be postulated that HNO could
activate the ferric enzyme to levels
similar to what is observed when
NO binds to the ferrous enzyme. To
determine whether HNO binds to
ferrous or ferric heme sGC, we
measured sGC activation when the
enzyme was in different oxidation
states (Fig. 4B). Our results show
that NO andHNOdonors only acti-
vate ferrous sGC, as heme oxidation
with ferricyanide renders sGC
insensitive to activation by bothNO
and HNO donors. To test if this
effect could be due to heme loss, the
oxidized sGC was then re-reduced
with DTT. The re-reduced sGCwas
again sensitive to DEANO and AS
(but not to NCTFA, likely because
of the scavenging action of millimo-
lar levels of DTT, as shown before
(see Fig. 3B)).
It has been reported that heme-
bound sGC can exchange with an
exogenous ferrous nitrosyl heme
source resulting in activation via
formation of the sGC-Fe2-NO
complex (41). Also, heme-free en-
zyme is capable of incorporating a
ferrous-nitrosyl heme, resulting in
activation (41). Interestingly, when
hemin chloride is mixed with AS, to
generate the corresponding ferrous
nitrosyl heme adduct in situ, and
incubated with heme-free sGC, the
enzyme is activated 6-fold. This sug-
gests that HNO nitrosylated hemin (the ferrous nitrosyl spe-
cies) can be made in solution and capable of incorporating into
heme-free sGC resulting in enzyme activation (Fig. 4C).
sGC Activity Is Inhibited by an HNO-Thiol Interaction—The
activation of sGC by Angeli’s salt shown in Figs. 2 and 5A repre-
sents a dose-response relationship up to 10 M. However, at the
highest concentration of donor (100 M) Angeli’s salt begins to
inhibit activity. The activation is likely occurring viaHNO ligation
to the heme iron (see above). The inhibition at high concentration
could be due to HNO interacting with a second lower affinity
inhibitory site on sGC. Significantly, the inhibition of sGC activity
at thehighAngeli’s salt concentrationwasprotectedagainst by the
presence of DTT, a reagent known to reduce oxidized thiol spe-
cies. Because thiol modification is known to inhibit the NO-acti-
vated formof sGC,we investigated the possibility that at high con-
centrations HNO was modifying sGC thiols and leading to
inhibition of activation of sGC.
FIGURE 3. Activation of sGC by HNO donors is not due to NO. A, effect of desferoxamine on sGC activation.
The effect of excess NO (DEANO) or HNO (NCTFA, Angeli’s salt) donors (100 M) on sGC (3.6 g final) activity was
measured in the presence or absence of 10 M of the metal chelator (desferrioxamine, DFX) for 15 min at 37 °C.
Data represents the average of triplicate measurements reported as specific activity (nmol of cGMP mg1
min1). B, effect of DTT on sGC activation. We measured sGC (19 g final) activation by 100 M NO (DEANO) or
HNO (NCTFA, Angeli’s salt) donors in the presence or absence of 10 mM DTT for 15 min at 37 °C. Data represents
the average of triplicate measurements reported as specific activity (nmol of cGMP mg1 min1).
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We isolated the interaction between HNO and the thiols
(from possible heme interactions) by removing the iron heme
and substituting it with PPIX. PPIX binds the enzyme to acti-
vate it to the same level as the NO
ferrous heme-bound form of sGC
and is kinetically indistinguishable
from this NO-activated form (42).
The iron-free PPIX thus eliminates
the possible interaction of HNO
with the heme iron. Thus, apo-sGC
activated with 100 nM PPIX (incu-
bated for 5 min at 37 °C) was then
co-incubated with HNO and NO
donors (Fig. 5B). PPIX alone acti-
vated apo-sGC 52-fold over basal
activity (specific activity of 85.17
versus 1.63 nmol of cGMP min1
mg1). This was unchanged in the
presence of NO (100 M DEA/NO).
However, when apo-sGC activated
with PPIX was co-incubated with
Angeli’s salt, it was inhibited by 50%
(38.21 nmol of cGMPmin1mg1).
Likewise, when the same treatment
was done with NCTFA, PPIX-acti-
vated apo-sGCwas inhibited by 33%
(58.49 nmol of cGMPmin1mg1).
DISCUSSION
These experiments show that the
HNO donors AS and NCTFA sig-
nificantly activate purified bovine
sGC through a direct interaction of
HNOwith the ferrous heme of sGC.
To date, NO has been considered to
be the only nitrogen oxide capable
of activating sGC (17). However,
due to a variety of studies alluding to
possible biological actions of HNO
occurring via cGMP pathways (12–
15, 43, 44) it appears that HNOmay
in fact activate sGC. It has been pro-
posed that HNO conversion to NO
by various physiological oxidants
(28) could be responsible for the
increase in cGMP observed in vitro.
However, the observation that
HNO also elicits cGMP-dependent
effects in the presence of NO scav-
engers (45) indicates that there may
be a direct interaction between
HNO and sGC. In contrast to the
results presented herein, Dierks and
Burstyn (17) previously showed that
HNOderived fromAShad no direct
stimulatory effect on sGC and did
not alter the ability of NO donors to
activate sGC. However, these early
experiments examined the interaction of HNO and sGC in the
presence of 10mMDTT, a vital component ofmost aerobic sGC
studies due to the oxidative instability of the heme and protein
Regulation of sGC by HNO
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thiols (46). This amount of DTT is sufficient to scavenge the
HNO produced from AS and prevent any direct interaction
(47). To eliminate the potentially confounding effect of high
levels of exogenous thiols, the studies described herein were
performed anaerobically and in the absence of high levels of
exogenous thiols.
It is clear that sGC can be activated by HNO donors AS and
NCTFA (Fig. 2). As stated earlier, the fact that these two donors
are structurally distinct and release HNO via completely differ-
ent mechanisms indicates that HNO is the activating species
and not impurities, the donors themselves, or other decompo-
sition by-products.
In anaerobic solution, the concentration of anNO donor can
be reasonably correlated to the amount of available NO in solu-
tion. Thus, the maximum enhancement of sGC activity by
DEA/NO, which was observed at 1 M (Fig. 2), corresponds
to a threshold of 2 M NO because DEA/NO releases 2 eq of
NO (48). The minimum threshold for both AS and NCTFA
is 	100 M, however, correlation of donor concentration to
available HNO concentration is significantly hampered by the
fact that HNO self-consumes (Reaction 5) (27).
HNO  HNO3 HONNOH3 N2O  H2O
REACTION 5
Despite a relatively high rate constant (8  106 M1 s1; Ref.
33), the rate of dimerization is highly coupled to the HNO con-
centration given the second-order dependence.
The kinetics of HNO release from AS and NCTFA are quite
different. The decomposition of AS is very fast (t1⁄2  2–3 min,
pH 7.4, 37 °C) (27) and will result in a large, initial spike in the
concentration of HNO during the time course of the assay. In
contrast, the longer half-life of NCTFA (t1⁄2 	 1 h, pH 7.4, at
room temperature (23)) will produce a lower steady state con-
centration of HNO. Although these two donors are expected to
release equal amounts of HNO (one equivalent of HNO per
donor), the faster release of HNO fromASwill facilitate greater
self-consumption and thus reduce the overall amount of HNO
available to react with other targets such as the sGC heme (49).
This reduction in available HNO at high AS concentrations
likely contributes to the biphasic nature of the activation profile
of AS compared with those of DEA/NO and NCTFA (49).
The higher peak concentration of HNO with AS may also
contribute to the biphasic nature of its activation of sGC as
opposed to NCTFA. In Fig. 2 the activation of sGC by Angeli’s
salt is attenuated at the highest concentration (100M). Further
experiments probing this effect revealed that HNO inhibits
sGC activity by interacting at a second site distinct from the
heme (Fig. 5B). That is, in the absence of a metal ligation site,
NO has no effect on sGC activity. However, under these same
conditions, HNO significantly inhibits enzyme activity, impli-
cating a second site of interaction. Based on the known chem-
istry ofHNOthis ismost likely a thiol cysteine target, consistent
with the observed protection by DTT (Fig. 3B) (20, 50). Signif-
icantly, recent data by Sayed et al. (51) characterized the forma-
tion of S-nitrosated cysteine residues in sGC , indicating possi-
ble thiol modification by nitrogen oxides. Thus, there may be a
subset of sGC thiols that are subject to biochemical modifica-
tion and are important to the physiological regulation of sGC
FIGURE 4. HNO activation of sGC depends on the presence of ferrous heme. A, effect of heme removal on sGC activation. We measured the ability of NO
(DEANO) or HNO (NCTFA, Angeli’s salt) donors to activate sGC with and without heme. Untreated (heme bound) and treated (heme removed) sGC (19 g final)
were assayed for activity in the presence of 100 M donors for 15 min at 37 °C. Data represents the average of triplicate measurements reported as fold-
activation over basal activity (no donor). B, effect of heme redox state on sGC activation. We compared the ability of NO (DEANO) or HNO (NCTFA, Angeli’s salt)
donors to activate reduced and oxidized sGC. sGC was treated with ferricyanide to oxidize heme and re-reduced with DTT. Ferrous (reduced, untreated), ferric
(oxidized, treated with ferricyanide), and ferric  DTT (re-reduced, treated with ferricyanide then DTT) sGC (3.5 g final) were assayed for activity in the
presence of 100 M donors for 12 min at 37 °C. Data represents the average of triplicate measurements reported as fold-activation over basal activity (no
donor). C, effect of ferric heme and HNO on sGC activation. Heme was removed from sGC and activity was measured in the presence of Angeli’s salt (100 M)
alone or Angeli’s salt (100 M) and hemin chloride (0.1 M). Data represents the average of triplicate measurements reported as specific activity (nmol of cGMP
mg1 min1).
FIGURE 5. HNO inhibits activated sGC in a thiol dependent manner.
A, effect of HNO (Angeli’s salt) on sGC activity. We measured sGC (19 g final)
activation by an HNO donor (Angeli’s salt) in the presence or absence of 10
mM DTT for 15 min at 37 °C. Data represents the average of triplicate meas-
urements reported as specific activity (nmol of cGMP mg1 min1). B, effect of
HNO donors on PPIX-activated sGC. Heme was removed from sGC and it was
incubated in the absence (control) or presence of PPIX (100 nM) for 5 min at
37 °C. Activity was measured in the absence of PPIX, the presence of PPIX
alone, or PPIX co-incubated with DEANO (100 M), Angeli’s salt (100 M), or
NCTFA (100 M). Data represents the average of triplicate measurements
reported as specific activity (nmol of cGMP mg1 min1).
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activity. Significantly, cysteine thiol modification of numerous
proteins by HNO has been reported, further establishing pro-
tein thiols as a significant target forHNObiology (see for exam-
ple, Refs. 52 and 53). Moreover, identification of HNO-thiol
adducts has been established via mass spectral analysis (54).
Addition of DTT enhanced the activation of sGC by AS
while reducing the effect of NCTFA (Fig. 3B). This appar-
ently selective inhibition of the NCTFA versus AS is likely
due to the fact that AS generates NO (as a minority product)
along with HNO (31). Because the trace amounts of NO
generated rapidly reacts with excess HNO (33), this typically
precludes any biological activity associated with NO from
AS. However, when HNO is selectively scavenged by DTT
(which is a faster reaction than the HNO-NO reaction (49)),
NO is allowed to survive and activate sGC. Because NCTFA
decomposition is not known to generate significant amounts
of NO, this is not an issue with this
donor. Another possible explana-
tion that can also contribute to
this observation is related to the
dissimilar kinetics of donor
decomposition. We have shown
that HNO at low concentrations
can activate sGC via the ferrous
heme, and, as the concentration is
increased, it attenuates its own
activation by reacting at a second
site (via thiol interaction). In the
case of AS, when DTT is added it
competitively scavenges enough
HNO to prevent the inhibitory
interaction with the thiols or sim-
ply reverses the HNO-mediated
thiol modifications, but is unable
to prevent HNO from activating
via the heme (implying rapid asso-
ciation of HNO to the ferrous
heme of sGC). During the decom-
position of NCTFA, however,
DTT is sufficient to scavenge the
low, sustained concentration of
HNO, thereby preventing activa-
tion. Despite the kinetic differ-
ences in decomposition, these
results highlight the fact that
HNO is mediating the sGC effects.
Based on knownHNO chemistry,
we hypothesize that HNO canmod-
ulate sGC activity by binding to the
sGC heme, modifying critical sGC
thiols or a combination of both
effects. Although our data are con-
sistent with the idea that HNO can
modify sGC thiols and result in sGC
inhibition, the experiments pre-
sented here unambiguously show
thatHNOdirectly interactswith the
ferrous heme of sGC (Fig. 4). It was
unexpected that HNO activated the ferrous but not the ferric
form of sGC because HNO readily forms ferrous nitrosyl com-
plexes by reductive nitrosylation of a variety of ferric heme- and
non-heme proteins (40, 55–58). Reductive nitrosylation of sGC
maybe kinetically slow comparedwith dimerization or reaction
with protein thiols. The fact thatmany of the ferric systems that
undergo reductive nitrosylation do not contain thiols, whereas
bovine lung sGC contains multiple cysteine residues may be a
significant factor in the resistance of sGC to this reaction. Fur-
thermore, ferric sGC has been suggested to be unusually sub-
stitutionally inert because addition of very high concentrations
of azide and cyanide (150 and 4mM, respectively) were required
to induce changes in ferric sGC spectra (59). Because dimeriza-
tion of HNO inhibits the ability to produce millimolar concen-
trations ofHNO in solution, a similar studywith anHNOdonor
is not possible.
FIGURE 6. Proposed mechanisms for the effects of HNO on sGC activity. Note, the possible and/or likely
products of sGC thiol oxidation by excess HNO are shown. The exact nature of the products and the sites of
these cysteine thiols are not known.
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Interaction betweenHNO and the ferrous heme of sGC gen-
erates activated enzyme. Previous reports suggest that HNO
forms a stable complex with ferrous heme proteins (18, 60–62)
and this may also be the case with sGC. Indeed, in current
studies utilizing a truncated sGC protein containing only the
heme domain, a HNO-ferrous heme adduct was been
observed.4 According to the currently accepted mechanism of
sGC activation by NO (63), binding of NO to the pentacoordi-
nate ferrous histidyl heme results in cleavage of the axial His105
bond and associated conformational changes. The preference
of ferrous porphyrin nitrosyl complexes for pentacoordination
has been long established (for example, see Refs. 64 and 65).
The strong trans effect of NO is a result of the donation of the
* electron from NO into the Fe2 dz2 orbital, which weakens
the trans ligand bond enough to cleave (66). In contrast, CO
complexes are preferentially hexacoordinate because CO is a
weaker trans director due to both the absence of ligand * elec-
trons and the importance of  backbonding compared with 
bonding in CO association (66). Unlike NO, there is no occu-
pancy of the * orbital in HNO thus predicting no analogous
trans-activation. However, in the Mb-HNO complex charac-
terized by Immoos et al. (61) the iron-axial His distance was
significantly longer for the HNO-bound complex compared
with the NO-bound complex. Moreover, ferrous nitroxyl com-
plexes are isoelectronic with cobalt nitrosyl complexes, which
are generally considered to have a charge distribution of
CoIIINO (67). The equilibrium constant for addition of a sec-
ond axial ligand to cobalt (II) porphyrin complexes is small (68),
supporting the possibility that ferrous nitroxyl complexes can
be pentacoordinate.
It should be noted that HNO can be considered as the sim-
plest form of an alkyl-nitroso molecule and sGC is not signifi-
cantly activated by a variety of short and long chain length alkyl-
nitroso compounds (69, 70). Furthermore, the current study
cannot exclude the possibility that the ferrous nitroxyl complex
of sGC is oxidized to the active ferrous nitrosyl complex. The
analogous Mb-HNO complex is a good reductant as indicated
by its facile oxidation by methyl viologen (71). HNO is also a
fairly good one-electron oxidant (0.1 V versus NHE for HNO,
H/H2NO, pH 7) (72) and excess HNO may oxidize bound
HNO to NO. Further spectral analyses are currently underway
to investigate this possibility.
The combined results presented herein are summarized as
follows: 1) HNO activates sGC via coordination to the ferrous
enzyme, akin to NO-mediated activation, 2) HNO does not
activate the oxidized ferric enzyme, 3) HNO modification of
regulatory thiols on sGC results in loss of activity, resulting in a
biphasic activity curve, lowHNOgives significant activation via
heme coordination and higher levels begin to attenuate this
activity. Fig. 6 schematically depicts these interactions of HNO
with sGC.
One of the most pressing and provocative questions regard-
ing HNO remains: is HNO an endogenously generated physio-
logical signaling agent? To date, there is no clear evidence that
this is the case. Although a variety of biologically accessible
chemical processes have been reported that are capable of gen-
erating HNO (36), there is no evidence that any of these pro-
cesses represent an endogenous source of HNO for signaling
purposes. However, considering the extreme potency and spec-
ificity of the actions of HNO in, for example, the cardiovascular
system (see below) it is intriguing to speculate that HNO is
generated endogenously for the purpose of regulating cardiac
function. Regardless, proper examination of this issue is clearly
warranted.
There is growing interest in the cardiovascular actions of
HNO (for example, see Ref. 73). Studies suggest that the use of
HNO to treat heart failure has numerous advantages over NO-
releasing drugs because HNO causes increased left ventricular
contractility and reduced cardiac preload while decreasing
peripheral vascular resistance; it is also additive to the beneficial
actions of -agonists (74). Further still, one of the principal
pharmacological interventions for heart failure, administration
of organic nitrates, suffers from the development of tachyphy-
laxis, which severely limits the clinical use of this family of ther-
apeutics. Interestingly, HNO donors do not induce tolerance
and remain equipotent in the circulation of animals made tol-
erant to glyceryl trinitrate (75), suggesting that HNOwill main-
tain its beneficial activity long after NO-based treatment has
diminished. There is also a risk of systemic hypotension and
headache (dilatation of the cerebral vasculature) with the use of
organic nitrates (76) that may be avoided with the use of an
HNO donor.
Our data provide a potential explanation for this favorable
profile of HNO donors; the mechanism by which they activate
sGC is self-limiting. Thus, we have demonstrated unequivo-
cally that HNO can activate sGC (e.g. dilate the vasculature) via
interaction at the heme site, but at higher concentrations will
attenuate its own activation (via interactions at the regulatory
thiol sites), thus minimizing the possibility of excessive stimu-
lation and tolerance. This work therefore clearly demonstrates
a potential advantage of using HNO, compared with NO
donors as vasodilatory agents in a number of cardiovascular
disorders.
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